Newly Published White Paper Shows How Plasmid-IQ Design Enhances 
Performance, Stability, and Production Efficiency 

King of Prussia, PA (May 7, 2025) — SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced the launch of Plasmid-IQ Design, its innovative and proprietary plasmid engineering platform, designed to optimize genetic constructs and significantly enhance their performance, stability, and production efficiency. 

Plasmids serve as critical raw materials in the development and manufacturing of cell and gene therapies, vaccines, and biologics. Inefficiencies stemming from poorly designed plasmids can lead to reduced yields, increased costs, and significant delays. Plasmid-IQ Design directly addresses these challenges by applying scientifically validated design principles to create superior plasmid constructs. 

“Plasmid design is a cornerstone of modern biological research, and optimizing its structure is critical to achieving research and manufacturing goals efficiently,” said John Lee, Global Head of Cell and Gene Therapy. “Plasmid-IQ Design addresses often overlooked challenges in plasmid engineering and offers tailored solutions that enhance stability, scalability, and performance. Our collaborative approach leverages deeply nuanced biology while also tailoring that biology to the unique needs of our advanced therapy customers.” 

SK pharmteco’s Plasmid-IQ Design offers a comprehensive service that enhances plasmid design by optimizing genetic sequences, vector compatibility, and overall stability. This approach ensures higher expression levels of the desired therapeutic genes and improved reproducibility in downstream applications.  

Additionally, Plasmid-IQ Design fosters a collaborative partnership with clients, working together to optimize sequences from the outset. This proactive approach minimizes the need for extensive rework often associated with conventional plasmid design methods, ultimately saving valuable time and resources. 

Key features and benefits of Plasmid-IQ Design include: 

• Sequence optimization: Enhancing gene expression for improved protein production. 

• Improved vector selection: Tailoring vector choice for specific application requirements. 

• Increased stability: Minimizing mutations and ensuring the integrity of the genetic construct. 

• Customizable plasmid libraries and advanced vector systems: Providing flexible solutions to meet diverse research and manufacturing needs. 

• Establishment of Plasmid Master Cell Banks (MCBs): Ensuring a consistent and reliable source of high-quality plasmids for large-scale production. 

Additionally, the launch of Plasmid-IQ Design represents a powerful synergy with SK pharmteco’s established plasmid manufacturing capabilities, particularly its proprietary Plasmid-IQ line technology. While Plasmid-IQ Design focuses on optimizing the design of genetic constructs to enhance performance, stability, and efficiency, Plasmid-IQ R&D, Plasmid-IQ HQ, and Plasmid-IQ GMP provide a robust and scalable manufacturing solution to bring those optimized designs to life. 

“SK pharmteco’s Plasmid-IQ line, offered on demand at any scale and royalty-free for manufacturing clients from preclinical R&D through CGMP production, is specifically designed to overcome manufacturing hurdles and accelerate development timelines,” said Lee. “By integrating the intelligent design capabilities of Plasmid-IQ Design with the efficient and scalable manufacturing of the Plasmid-IQ line, we provide our clients with a comprehensive solution to rapidly advance their gene and cell therapies towards patient benefit.” 

SK pharmteco is committed to ensuring its clients retain complete ownership of their intellectual property. Unless explicitly negotiated otherwise, all work related to plasmid design and optimization through Plasmid-IQ Design belongs solely to the customer, providing complete control and peace of mind over their proprietary plasmid constructs. 

A comprehensive white paper detailing the science and benefits behind the Plasmid-IQ Design platform is available by visiting here. 

### 

About SK pharmteco 
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.   

Contact: 
Keith Bowermaster, APR, CCMP 
Communications Consultant 
keith.bowermaster@skpt.com